Publication date: May 20, 2026
To better understand the mental health impacts of Long COVID, we examine the prospective association between Long COVID and risk of COVID-related post-traumatic stress disorder (PTSD) symptoms. We used baseline and follow-up data from the Michigan COVID-19 Recovery Surveillance Study, a population-based study of adults diagnosed with polymerase chain reaction-confirmed COVID-19 between March 2020 and May 2022 in Michigan (n = 3492). Baseline data were collected a median of 4. 4 months (interquartile range (IQR): 3. 4-5. 7 months) and follow-up data were collected a median of 18. 4 months (IQR: 15. 0-21. 3 months) after initial COVID-19 onset. We defined Long COVID at baseline as having not recovered to usual state of health 90 days or more after initial COVID-19 onset and having COVID-related PTSD symptoms at follow-up based on a six-item version of the PTSD Checklist for Civilians anchored to each individual’s COVID-19 diagnosis. We ran modified Poisson regression models adjusting for sociodemographic characteristics, pre-existing comorbidities, COVID-19 illness severity, survey mode, and phase of the pandemic when diagnosed with COVID-19. At baseline, 17. 0% of adults diagnosed with COVID-19 had Long COVID, and 10. 1% of adults reported COVID-related PTSD symptoms at follow-up. In the fully adjusted model, the risk of COVID-related PTSD symptoms was 2. 08 times higher (95% confidence interval: 1. 65-2. 63) among adults with Long COVID than among adults without Long COVID. Long COVID is prospectively associated with a higher risk of COVID-related PTSD symptoms suggesting a need to strengthen mental health screening, monitoring, and interventions among adults with this condition.
| Concepts | Keywords |
|---|---|
| 4months | Cohort |
| 90days | COVID-19 |
| Covid | Long COVID |
| Michigan | Post-traumatic stress disorder |
| Surveillance |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | long COVID |
| disease | MESH | post-traumatic stress disorder |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | PTSD |
| drug | DRUGBANK | Ranitidine |